Eszopiclone (Lunesta) for treatment of transient and chronic insomnia

American Family Physician

Volumn 71, Issue 12, 2005, Pages 2359-2360

  Wessell, Andrea M ^a   Weart, C Wayne ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BENZODIAZEPINE; ESZOPICLONE; ZALEPLON; ZOLPIDEM; ZOPICLONE;

CLINICAL TRIAL; DIZZINESS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; INSOMNIA; INTOXICATION; REVIEW; UNITED STATES;

DRUG EVALUATION; HUMANS; HYPNOTICS AND SEDATIVES; PIPERAZINES; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 21044448848     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (4)

1. Lunesta (package insert). Marlborough, Mass.: Sepracor, Inc., 2004. Accessed online May 2, 2005, at: http://www.lunesta.com/ PostedApprovedLabelingText.pdf.
2. Eszopiclone (Lunesta), a new hypnotic. Med Lett Drugs Ther 2005;47:17-9.
3. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-9.
4. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20:1979-91.